

# Sten Myrehaug

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5155302/publications.pdf>

Version: 2024-02-01

76  
papers

1,957  
citations

257450

24  
h-index

276875

41  
g-index

80  
all docs

80  
docs citations

80  
times ranked

2371  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. <i>Leukemia and Lymphoma</i> , 2008, 49, 1486-1493.	1.3	144
2	Reirradiation spine stereotactic body radiation therapy for spinal metastases: systematic review. <i>Journal of Neurosurgery: Spine</i> , 2017, 27, 428-435.	1.7	113
3	Vertebral Compression Fracture After Spine Stereotactic Body Radiation Therapy: A Review of the Pathophysiology and Risk Factors. <i>Neurosurgery</i> , 2018, 83, 314-322.	1.1	104
4	Imaging-Based Outcomes for 24 Gy in 2 Daily Fractions for Patients with de Novo Spinal Metastases Treated With Spine Stereotactic Body Radiation Therapy (SBRT). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 499-507.	0.8	83
5	MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. <i>Science Translational Medicine</i> , 2021, 13, eabj4011.	12.4	82
6	Spine Stereotactic Body Radiotherapy: Indications, Outcomes, and Points of Caution. <i>Global Spine Journal</i> , 2017, 7, 179-197.	2.3	79
7	Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview. <i>Frontiers in Oncology</i> , 2019, 9, 337.	2.8	74
8	A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. <i>Blood</i> , 2010, 116, 2237-2240.	1.4	63
9	Differentiating radiation necrosis from tumor progression in brain metastases treated with stereotactic radiotherapy: utility of intravoxel incoherent motion perfusion MRI and correlation with histopathology. <i>Journal of Neuro-Oncology</i> , 2017, 134, 433-441.	2.9	59
10	Evaluation of Glioblastoma Response to Therapy With Chemical Exchange Saturation Transfer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 713-723.	0.8	58
11	Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1577-1598.	1.1	58
12	Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. <i>Practical Radiation Oncology</i> , 2020, 10, e495-e507.	2.1	50
13	Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis. <i>Scientific Reports</i> , 2019, 9, 19830.	3.3	46
14	Quantitative <sup>68</sup> Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup> Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1406-1414.	5.0	40
15	Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 84-93.	1.2	39
16	Adverse Radiation Effect After Hypofractionated Stereotactic Radiosurgery in 5 Daily Fractions for Surgical Cavities and Intact Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 772-779.	0.8	36
17	Quantitating Interfraction Target Dynamics During Concurrent Chemoradiation for Glioblastoma: A Prospective Serial Imaging Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 736-746.	0.8	36
18	Volume of Lytic Vertebral Body Metastatic Disease Quantified Using Computed Tomography-Based Image Segmentation Predicts Fracture Risk After Spine Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 75-81.	0.8	35

#	ARTICLE	IF	CITATIONS
19	Image-Guided, Linac-Based, Surgical Cavity-Hypofractionated Stereotactic Radiotherapy in 5 Daily Fractions for Brain Metastases. <i>Neurosurgery</i> , 2019, 85, E860-E869.	1.1	34
20	A Treatment Planning and Acute Toxicity Comparison of Two Pelvic Nodal Volume Delineation Techniques and Delivery Comparison of Intensity-Modulated Radiotherapy Versus Volumetric Modulated Arc Therapy for Hypofractionated High-Risk Prostate Cancer Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e657-e662.	0.8	32
21	Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy. <i>Scientific Reports</i> , 2018, 8, 2475.	3.3	31
22	Spinal metastasis: diagnosis, management and follow-up. <i>British Journal of Radiology</i> , 2019, 92, 20190211.	2.2	29
23	MRI radiomics to differentiate between low grade glioma and glioblastoma peritumoral region. <i>Journal of Neuro-Oncology</i> , 2021, 155, 181-191.	2.9	29
24	Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 523-530.	2.4	28
25	Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter. <i>Radiotherapy and Oncology</i> , 2020, 142, 236-245.	0.6	27
26	Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. <i>Frontiers in Oncology</i> , 2021, 11, 628155.	2.8	27
27	Postoperative Stereotactic Body Radiotherapy for Spinal Metastases and the Impact of Epidural Disease Grade. <i>Neurosurgery</i> , 2019, 85, E1111-E1118.	1.1	26
28	Glioma consensus contouring recommendations from a MR-Linac International Consortium Research Group and evaluation of a CT-MRI and MRI-only workflow. <i>Journal of Neuro-Oncology</i> , 2020, 149, 305-314.	2.9	25
29	Local control and patterns of failure for radioresistant spinal metastases following stereotactic body radiotherapy compared to a radiosensitive reference. <i>Journal of Neuro-Oncology</i> , 2021, 152, 173-182.	2.9	24
30	Single-Fraction Stereotactic Radiosurgery Versus Hippocampal-Avoidance Whole Brain Radiation Therapy for Patients With 10 to 30 Brain Metastases: A Dosimetric Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 394-399.	0.8	23
31	Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation. <i>Journal of Neuro-Oncology</i> , 2021, 151, 267-278.	2.9	23
32	Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. <i>Cmaj</i> , 2019, 191, E574-E580.	2.0	21
33	Stereotactic Body Radiotherapy for Spinal Metastases at the Extreme Ends of the Spine: Imaging-Based Outcomes for Cervical and Sacral Metastases. <i>Neurosurgery</i> , 2019, 85, 605-612.	1.1	20
34	Accuracy and precision of apparent diffusion coefficient measurements on a 1.5T MR-Linac in central nervous system tumour patients. <i>Radiotherapy and Oncology</i> , 2021, 164, 155-162.	0.6	19
35	Glioblastoma (GBM) effects on quantitative MRI of contralateral normal appearing white matter. <i>Journal of Neuro-Oncology</i> , 2018, 139, 97-106.	2.9	18
36	Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. <i>Radiotherapy and Oncology</i> , 2021, 156, 258-265.	0.6	18

#	ARTICLE	IF	CITATIONS
37	Quantitative mapping of individual voxels in the peritumoral region of IDH-wildtype glioblastoma to distinguish between tumor infiltration and edema. <i>Journal of Neuro-Oncology</i> , 2021, 153, 251-261.	2.9	18
38	Spinal metastases: multimodality imaging in diagnosis and stereotactic body radiation therapy planning. <i>Future Oncology</i> , 2017, 13, 77-91.	2.4	17
39	The era of stereotactic body radiotherapy for spinal metastases and the multidisciplinary management of complex cases. <i>Neuro-Oncology Practice</i> , 2016, 3, 48-58.	1.6	16
40	Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes. <i>Oncologist</i> , 2019, 24, 1384-1394.	3.7	16
41	Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters. <i>Radiotherapy and Oncology</i> , 2021, 161, 159-165.	0.6	14
42	Hypofractionated Stereotactic Radiation Therapy for Intact Brain Metastases in 5 Daily Fractions: Effect of Dose on Treatment Response. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 342-350.	0.8	14
43	Chemical exchange saturation transfer MRI in central nervous system tumours on a 1.5T MR-Linac. <i>Radiotherapy and Oncology</i> , 2021, 162, 140-149.	0.6	14
44	Prognostic Factors Associated With Surviving Less Than 3 Months vs Greater Than 3 Years Specific to Spine Stereotactic Body Radiotherapy and Late Adverse Events. <i>Neurosurgery</i> , 2021, 88, 971-979.	1.1	13
45	Material deprivation and access to cancer care in a universal health care system. <i>Cancer</i> , 2020, 126, 4545-4552.	4.1	12
46	Postoperative stereotactic body radiotherapy for spinal metastases. <i>Chinese Clinical Oncology</i> , 2017, 6, S18-S18.	1.2	12
47	Inter-fraction dynamics during post-operative 5 fraction cavity hypofractionated stereotactic radiotherapy with a MR LINAC: a prospective serial imaging study. <i>Journal of Neuro-Oncology</i> , 2022, 156, 569-577.	2.9	12
48	A rapid inversion technique for the measurement of longitudinal relaxation times of brain metabolites: application to lactate in high-grade gliomas at 3 T. <i>NMR in Biomedicine</i> , 2016, 29, 1381-1390.	2.8	10
49	Positional Accuracy of Treating Multiple Versus Single Vertebral Metastases With Stereotactic Body Radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 231-237.	1.9	10
50	Mature Imaging-Based Outcomes Supporting Local Control for Complex Reirradiation Salvage Spine Stereotactic Body Radiotherapy. <i>Neurosurgery</i> , 2020, 87, 816-822.	1.1	10
51	Stereotactic Ablative Radiotherapy for the Management of Liver Metastases from Neuroendocrine Neoplasms: A Preliminary Study. <i>Neuroendocrinology</i> , 2022, 112, 153-160.	2.5	10
52	A randomized phase II/III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for patients with spinal metastases (NCT02512965).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS10129-TPS10129.	1.6	10
53	Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211096.	1.9	9
54	BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults. <i>Brain Pathology</i> , 2020, 30, 515-523.	4.1	8

#	ARTICLE	IF	CITATIONS
55	Stereotactic radiosurgery for resected brain metastasis: Cavity dynamics and factors affecting its evolution. <i>Journal of Radiosurgery and SBRT</i> , 2018, 5, 191-200.	0.2	8
56	Improved dosimetric accuracy with semi-automatic contour propagation of organs at risk in glioblastoma patients undergoing chemoradiation. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 45-53.	1.9	7
57	The Initial Step Towards Establishing a Quantitative, Magnetic Resonance Imaging-Based Framework for Response Assessment of Spinal Metastases After Stereotactic Body Radiation Therapy. <i>Neurosurgery</i> , 2021, 89, 884-891.	1.1	6
58	Spine Stereotactic Body Radiotherapy for Prostate Cancer Metastases and the Impact of Hormone Sensitivity Status on Local Control. <i>Neurosurgery</i> , 2022, 90, 743-749.	1.1	6
59	Why hypofractionate stereotactic radiosurgery for brain metastases?. <i>CNS Oncology</i> , 2016, 5, 111-113.	3.0	5
60	Clinical Image Coregistration Variability on a Dedicated Radiosurgery Unit. <i>Neurosurgery</i> , 2019, 85, E101-E108.	1.1	5
61	Quantification of pulsed saturation transfer at 1.5T and 3T. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 1684-1699.	3.0	5
62	Risk of Cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors: A Population-Based Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 935-944.	4.9	5
63	Predicting survival in patients with glioblastoma using MRI radiomic features extracted from radiation planning volumes. <i>Journal of Neuro-Oncology</i> , 2022, 156, 579-588.	2.9	5
64	A pilot study of everolimus and radiation for neuroendocrine liver metastases. <i>Endocrine-Related Cancer</i> , 2021, 28, 541-548.	3.1	4
65	Incidence and Predictors of Second Primary Cancers in Patients With Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2021, 7, 1718.	7.1	4
66	Rapidly progressive bone destruction of the finger as first presentation of systemic metastases from lung cancer. <i>BMJ Case Reports</i> , 2010, 2010, bcr0520091912-bcr0520091912.	0.5	4
67	Economic Analysis of Adjuvant Chemoradiotherapy Compared with Chemotherapy in Resected Pancreas Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 4193-4203.	1.5	3
68	ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma. <i>Data in Brief</i> , 2021, 35, 106950.	1.0	3
69	Investigation of irradiated volume in linac-based brain hypo-fractionated stereotactic radiotherapy. <i>Radiation Oncology</i> , 2017, 12, 117.	2.7	2
70	The benefits of upfront primary tumor resection for metastatic small bowel neuroendocrine tumors: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 620-620.	1.6	2
71	Symptom burden at the end of life for neuroendocrine tumors: A population-based analysis of patient-reported outcomes.. <i>Journal of Clinical Oncology</i> , 2019, 37, 297-297.	1.6	2
72	Survival and cost associated with chemotherapy and chemoradiotherapy among resected pancreas cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 351-351.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Proof of concept for stereotactic body radiation therapy in the treatment of functional neuroendocrine neoplasms. <i>Journal of Radiosurgery and SBRT</i> , 2020, 6, 321-324.	0.2	1
74	LGG-01. BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENT AND YOUNG ADULT. <i>Neuro-Oncology</i> , 2019, 21, ii98-ii98.	1.2	0
75	Hospitalizations in elderly glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21529-e21529.	1.6	0
76	Risk of cancer-specific death for patients diagnosed with neuroendocrine tumors: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4605-4605.	1.6	0